Kairos Pharma, Ltd. (NYSE:KAPA) stock is trading higher on Tuesday, with a strong session volume of 221 million compared to the average volume of 874.3K as per data from Benzinga Pro. The company on Tuesday released safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in…
Continue reading...